Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT
Anthony A Amato,Michael G Hanna,Pedro M Machado,Umesh A Badrising,Hector Chinoy,Olivier Benveniste,Ananda Krishna Karanam,Min Wu,László B Tankó,Agnes Annette Schubert-Tennigkeit,Dimitris A Papanicolaou,Thomas E Lloyd,Merrilee Needham,Christina Liang,Katrina A Reardon,Marianne de Visser,Dana P Ascherman,Richard J Barohn,Mazen M Dimachkie,James A L Miller,John T Kissel,Björn Oskarsson,Nanette C Joyce,Peter Van den Bergh,Jonathan Baets,Jan L De Bleecker,Chafic Karam,William S David,Massimiliano Mirabella,Sharon P Nations,Hans H Jung,Elena Pegoraro,Lorenzo Maggi,Carmelo Rodolico,Massimiliano Filosto,Aziz I Shaibani,Kumaraswamy Sivakumar,Namita A Goyal,Madoka Mori-Yoshimura,Satoshi Yamashita,Naoki Suzuki,Masashi Aoki,Masahisa Katsuno,Hirokazu Morihata,Kenya Murata,Hiroyuki Nodera,Ichizo Nishino,Carla D Romano,Valerie S L Williams,John Vissing,Lixin Zhang Auberson,RESILIENT Study Extension Group,Susan Walters,Dave Hathorn,Sam Salman,Melanie Burk,Ruby Chen,Mary Jenkins,Carolyn Sue,Susan Mathers,Ruth Krasniqi,Lisa Mottram,Katie Fitzgerald,James Howe,Hanne Files,Linda Wagemaekers,Peter De Jonghe,Delphine Mahieu,Tom Heremans,Kathy de Koning,Katrien De Mey,Stefanie Cardoen,Chantal Miclotte,Marie-Odile Bioul,Anne Mette Autzen,Julia Rebecka Dahlqvist,Martin Jorsal,Nanna Witting,Jane Pedersen,Kirsten Knak,Linda Andersen,Maj-Brit Tanderup Joergensen,Jean Yves Hogrel,Laurent Gilardin,Gwenn Ollivier,Nicolas Champtiaux,Valérie Decostre,Aude Rigolet,Charlotte Lilien,Yves Allenbach,Anne Simon,Damien Bachasson,Chiara De Fino,Matteo Lucchini,Assunta Bianco,Francesco Losavio,Luca Bello,Ilaria Martinelli,Claudio Semplicini,Alessandra Gaiani,Marta Ballabio,Chiara Bussolino,Angela Campanella,Maria Pasanisi,Simona Portaro,Filippo Cavallaro,Fiammetta Biasini,Daniela Parisi,Alice Todeschini,Irene Volonghi,Silvia Rota,Simona Damioli,Hiroya Ono,Tomomi Shijo,Rumiko Izumi,Tetsuya Akiyama,Kensuke Ikeda,Noritaka Wakasugi,Tomoya Kawazoe,Asami Tasaki,Miho Murata,Takako Saotome,Yuki Aihara,Yosuke Ariake,Mai Fujiwara,Mizuki Takeuchi,Takayuki Tateishi,Koyo Tsujikawa,Kuniyuki Endo,Aya Ogura,Seiya Noda,Hirotaka Nakanishi,Kazuhiro Ikumi,Daisuke Ito,Makoto Hattori,Kiyoaki Takeda,Kenji Yoshimura,Rie Kanki,Michiyo Taniguchi,Satoshi Nakano,Maiko Hayashi,Minako Wada,Ayumi Murakami,Masaya Hironishi,Yasuhiro Hiwatani,Masaaki Yasui,Masae Izawa,Jinsoo Koh,Maki Hosokawa,Megumi Mori,Yoshiaki Nakayama,Shoko Yorozu,Junko Taruya,Chigusa Ohno,Shinji Kawasaki,Yukihide Nishimura,Yoshimichi Miyazaki,Naoko Matsui,Hiroki Yamazaki,Taiki Furumoto,Teruaki Masuda,Yasuhiro Yonemochi,Nozomu Tawara,Koutarou Takamatsu,Marjolein van Heur-Neuman,Zaida Koeks,Chiara Straathof,Martha Mosselman,Yvonne Krom,Alexander Lipka,E Strijbos,E Niks,J Verschuuren,Filip Eftimov,Guido Clerx,Tamar Gibson,Anneke van der Kooi,Barbara Christen,Jens Petersen,Evelyne Cataldo,Dan Nguyen-Kim,Gustav Andreisek,Sebastian Frese,Violeta Mihaylova,Kallies Diana,Sandro Mueller,Andrea Boehler,Laura Hennelly,Natalia Budnik,Liying Xing,Kerry Guile,Cathleen Chabo,Heather Hunter,Dorothy Carman,Helen Pilkington,Maria Price,Philip Brown,Ann McNichol,Rory Durcan,Angela Green,Fairbarin Smith,Kathryn Walker,Sean O'Dowd,Louise Wibin,Ann Mcnichol,Claire McDonald,Julie Chadwick,S M Ammar Raza,Mahrajan Raman,Catherine Lambe,Hilary Prais,Nikki Harwood,Ammar Rita,Maharajan Raman,Diane Vassallo,James Lilleker,Shirley Caldwell,Armgan Khan,Andres Keichian,Mohanad Alzubaidi,Yeni Villegas,Allen Tupue,Ali Habeeb,Gaurika Bhagi,Kristen Beck,Tatiana Burbar,Leigh Mauldin,Zina Rasheed,Nancy Cline,Piper Harris,Kristy Osgood,Preethi Nimalka Sivakumar,Kulette Bootka,Vinodh Narayanan,Sidney Spector,Christine Kline,Mark Gonzalez,Mamatha Pasnoor,Jeffrey Statland,Maureen Walsh,Melenie Glen,Melissa Currence,Laura Herbelin,Mazen Dimachkie,Gabrielle Rico,Ayla McCalley,Katie Amato,Nikita Shah,Kevin Zinchuk,Kristen Roe,Jessica Rydingsward,Mohammed Salajegheh,Samantha Chused,Katherine Mirch,Thomas Cochrane,Patricia Flynn,Amanda Guidon,Sarah Cornacchio,Fernando Gonterman,Amy Ellrodt,Magen Bissell,Tyler Watkins,Ashley Robichaud,Grace Bwala,Katharine Nicholson,Patricia Andres,Melissa Arnold,Jaya Trivedi,Lauren Phillips,Sharon Chelnick,Adam Quick,Julie Agriesti,Filiz Muharrem,Miriam Freimer,Stanley Iyadurai,Wendy King,Amro Stino,Louise Mezache,Veena Matthew,Veronica Martin,Tahseen Mozaffar,Tiyonnoh Cash,Trisha Hufnagel,Caroline Peyronnard,Sonia Nayyar,Bethly Aubourg,Judith Pignac-Kobinger,Alexandra Almahuer,Alexyz Milian,Chelsea Miller,Eric Greidinger,Lisa Harlow,Kristen Riley,Lora Clawson,Alpa Uchil,Lisa Christopher-Stine,Rachel Slusher,Sowmya Kumble,Julie Khoury,Harpreet Kaur,Diana Dimitrova,Brooke Bernard,Colleen Anthonisen,Natasha Sundby,Erica Goude,Candace Aguilar,Carly Davis,Jaijeet Toor,Randev Sandhu,Linda Johnson,Michelle Cregan,Sasa Yang,Sarah Macabales,Corey Owens,Criag Mcdonald,James Ha,Lisa Williams,Alina Nicorici,Eric Henricson
DOI: https://doi.org/10.1212/WNL.0000000000011626
IF: 9.9
2021-03-23
Neurology
Abstract:Objective: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). Methods: Participants (aged 36-85 years) who completed the core study (RESILIENT [Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients]) were invited to join an extension study. Individuals continued on the same treatment as in the core study (10 mg/kg, 3 mg/kg, 1 mg/kg bimagrumab or matching placebo administered as IV infusions every 4 weeks). The co-primary outcome measures were 6-minute walk distance (6MWD) and safety. Results: Between November 2015 and February 2017, 211 participants entered double-blind placebo-controlled period of the extension study. Mean change in 6MWD from baseline was highly variable across treatment groups, but indicated progressive deterioration from weeks 24-104 in all treatment groups. Overall, 91.0% (n = 142) of participants in the pooled bimagrumab group and 89.1% (n = 49) in the placebo group had ≥1 treatment-emergent adverse event (AE). Falls were slightly higher in the bimagrumab 3 mg/kg group vs 10 mg/kg, 1 mg/kg, and placebo groups (69.2% [n = 36 of 52] vs 56.6% [n = 30 of 53], 58.8% [n = 30 of 51], and 61.8% [n = 34 of 55], respectively). The most frequently reported AEs in the pooled bimagrumab group were diarrhea 14.7% (n = 23), involuntary muscle contractions 9.6% (n = 15), and rash 5.1% (n = 8). Incidence of serious AEs was comparable between the pooled bimagrumab and the placebo group (18.6% [n = 29] vs 14.5% [n = 8], respectively). Conclusion: Extended treatment with bimagrumab up to 2 years produced a good safety profile and was well-tolerated, but did not provide clinical benefits in terms of improvement in mobility. The extension study was terminated early due to core study not meeting its primary endpoint. Clinical trial registration: Clinicaltrials.gov identifier NCT02573467. Classification of evidence: This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was safe, well-tolerated, and did not provide meaningful functional benefit. The study is rated Class IV because of the open-label design of extension treatment period 2.